Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Climb Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Climb Bio's position in the market.
Climb Bio (Nasdaq: CLYM) is hosting a virtual investor event on October 15, 2024, to provide updates on its development strategy for budoprutug, an anti-CD19 monoclonal antibody. The company has completed its transition to focus on immune-mediated diseases and plans to advance budoprutug to late-phase development in primary membranous nephropathy (pMN) by 2025. Clinical trials for systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) are planned for the first half of 2025.
Key highlights include:
- Additional promising data from the Phase 1b pMN study
- Potential for deep and durable B-cell depletion
- Advancement of a subcutaneous formulation
- Planned clinical trials in SLE and ITP
- Cash runway through 2027
The company aims to develop treatments for approximately 50 million patients in the U.S. with immune-mediated diseases.
Climb Bio (Nasdaq: CLYM) has announced that it will present data at the American Society of Nephrology Kidney Week 2024, taking place in San Diego, CA from October 23-27, 2024. The presentation will feature a poster titled 'A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy'.
The presenter will be Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center, Chief of the Division of Nephrology at St. Peter's Hospital, Chief of Clinical Research at St. Peter's Health Partners, and Clinical Scientist at Massachusetts General Hospital. The poster session, focusing on Membranous Nephropathy, FSGS, and Minimal Change Disease, is scheduled for October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT, with the poster board number TH-PO587.
Climb Bio (Nasdaq: CLYM) has announced its participation in William Blair's Transforming Autoimmune Diseases by Targeting CD19 event. The company will present and host investor meetings at this conference, which is scheduled for Wednesday, October 16, 2024, in New York, NY.
This event focuses on innovative approaches to treating autoimmune diseases, specifically targeting CD19. Climb Bio's involvement suggests their work aligns with this cutting-edge area of medical research. The conference provides an opportunity for Climb Bio to showcase their developments and engage with investors interested in advancements in autoimmune disease treatments.
Climb Bio (Nasdaq: CLYM) has announced a virtual investor event scheduled for October 15, 2024. The event will feature presentations from key management team members and an external expert, providing updates on the company's strategy and focus on developing therapeutics for immune-mediated diseases.
Presenters will include Aoife Brennan (President and CEO), Stephen Thomas (Board Member), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP of Clinical Development), Brett Kaplan (COO), and Frank Cortazar (Director of the New York Nephrology Vasculitis and Glomerular Center).
The event will offer an in-depth review of Climb Bio's lead asset, budoprutug, an anti-CD19 monoclonal antibody designed to treat various immune-mediated diseases. Budoprutug has shown B-cell depletion in early clinical trials. A live webcast and replay will be available on the company's website.
FAQ
What is the current stock price of Climb Bio (CLYM)?
What is the market cap of Climb Bio (CLYM)?
